BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 11511149)

  • 21. [Selective estrogen receptor modulators].
    Zasławski R; Surowiak P; Zabel M
    Pol Arch Med Wewn; 2004 Nov; 112(5):1393-8. PubMed ID: 15773525
    [No Abstract]   [Full Text] [Related]  

  • 22. Breast cancer chemoprevention: a review of selective estrogen receptor modulators.
    Johansen AM
    Clin J Oncol Nurs; 2005 Jun; 9(3):317-20. PubMed ID: 15973842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medications for Primary Prevention of Breast Cancer.
    Shieh Y; Tice JA
    JAMA; 2020 Jul; 324(3):291-292. PubMed ID: 32692377
    [No Abstract]   [Full Text] [Related]  

  • 24. Chemoprevention of breast cancer: recommendations and rationale.
    U.S. Preventive Services Task Force
    Ann Intern Med; 2002 Jul; 137(1):56-8. PubMed ID: 12093249
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Lippman SM; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
    JAMA; 2006 Jun; 295(23):2727-41. PubMed ID: 16754727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
    Jordan VC; Gapstur S; Morrow M
    J Natl Cancer Inst; 2001 Oct; 93(19):1449-57. PubMed ID: 11584060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The selective estrogen receptor modulators in breast cancer prevention.
    Li F; Dou J; Wei L; Li S; Liu J
    Cancer Chemother Pharmacol; 2016 May; 77(5):895-903. PubMed ID: 26787504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CORE breast-cancer prevention trial.
    Bradbury J
    Lancet Oncol; 2005 Jan; 6(1):8. PubMed ID: 15672490
    [No Abstract]   [Full Text] [Related]  

  • 29. ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists: Number 39, October 2002. Selective estrogen receptor modulators.
    American College of Obstetricians and Gynecologists
    Obstet Gynecol; 2002 Oct; 100(4):835-43. PubMed ID: 12387278
    [No Abstract]   [Full Text] [Related]  

  • 30. Raloxifene for breast cancer prevention.
    Plouffe L
    JAMA; 2001 Apr; 285(16):2079. PubMed ID: 11311092
    [No Abstract]   [Full Text] [Related]  

  • 31. Raloxifene examined for breast cancer prevention.
    Young D
    Am J Health Syst Pharm; 2007 Sep; 64(17):1774. PubMed ID: 17724350
    [No Abstract]   [Full Text] [Related]  

  • 32. ACOG practice bulletin. Selective estrogen receptor modulators. Number 39, October 2002 (replaces Committee Opinion Number 224, October 1999).
    American College of Obsterticians and Gynecologists Committee on Practice Bulletins-Gynecology
    Int J Gynaecol Obstet; 2002 Dec; 79(3):289-98. PubMed ID: 12501867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [What do we think about selective estrogen receptor modulators?].
    Cortet B
    Rev Med Interne; 2001 Dec; 22(12):1173-6. PubMed ID: 11794886
    [No Abstract]   [Full Text] [Related]  

  • 34. Breast cancer chemoprevention: current status and future directions.
    Wickerham DL; Tan-Chiu E
    Semin Oncol; 2001 Jun; 28(3):253-9. PubMed ID: 11402435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Summaries for patients. Using medication to prevent breast cancer: recommendations from the United States Preventive Services Task Force.
    Ann Intern Med; 2002 Jul; 137(1):I62. PubMed ID: 12093267
    [No Abstract]   [Full Text] [Related]  

  • 36. Upstaging tamoxifen? New classes of drugs emerging for breast cancer.
    Twombly R
    J Natl Cancer Inst; 2002 Apr; 94(7):474-5. PubMed ID: 11929942
    [No Abstract]   [Full Text] [Related]  

  • 37. [Molecular mechanism tissue-specific actions of selective estrogen receptor modulators].
    Urano T
    Nihon Ronen Igakkai Zasshi; 2006 Mar; 43(2):147-51. PubMed ID: 16683636
    [No Abstract]   [Full Text] [Related]  

  • 38. SERMs for the treatment and prevention of breast cancer.
    Swaby RF; Sharma CG; Jordan VC
    Rev Endocr Metab Disord; 2007 Sep; 8(3):229-39. PubMed ID: 17440819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Raloxifene and endometrial cancer.
    Sismondi P; Biglia N; Ujcic E; Ponzone R; Roagna R
    Tumori; 2001; 87(5):S18-9. PubMed ID: 11765199
    [No Abstract]   [Full Text] [Related]  

  • 40. Toward optimal health: advances in breast cancer detection and management. Interview by Jodi R. Godfrey.
    Chlebowski RT
    J Womens Health (Larchmt); 2008 Sep; 17(7):1067-70. PubMed ID: 18774890
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.